Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry

Abstract Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell transplant. This analysis investigated the impact of lenalidomide-bortezomib-dexamethasone (RVd) i...

Full description

Bibliographic Details
Main Authors: Sikander Ailawadhi, Hans C. Lee, James Omel, Kathleen Toomey, James W. Hardin, Cristina J. Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Prashant Joshi, Ying-Ming Jou, Jorge Mouro, Edward Yu, Rafat Abonour
Format: Article
Language:English
Published: Nature Publishing Group 2024-11-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01177-6

Internet

https://doi.org/10.1038/s41408-024-01177-6

Similar Items